Company
Our purpose
On a mission for India.
Immuneel is committed to dramatically increase the access to transformational cell-based immunotherapies for cancer patients in India.
India’s own
The “Neel” in Immuneel refers to indigo, a natural blue dye – a colour synonymous with hope and possibility – a dye that is unique and India’s gift to the world.
Immuneel is an Indian company with a global outlook. Our ambition and effort is to make cell therapies affordable in India, and has the potential to enable access globally.
Delivering on our purpose, we are bringing in next-generation cell therapies, harnessing the bioengineered immune cell affordably, revolutionizing cancer care in India and giving hope to our patients.
Visionary leadership
Our leadership team unites us in our purpose to develop and deliver high quality affordable cell therapies through disruptive technologies and to make India a preferred destination for advanced cancer care and treat an under-served patient population.
Board Director & Co-founder
Chairperson Biocon Limited
The leading figure in Indian biotech for four decades, a well-respected entrepreneur, stateswoman for the industry.
Board Director & Co-founder
Cancer Physician, Columbia University, Scientific Co-founder, Vor Biopharma
Co-founder
Managing Partner, 5 AM ventures
Physician and Life Sciences focused investor, Director – Advisory Council of Princeton University’s Department of Molecular Biology.
Chief Executive Officer, Immuneel Therapeutics
A seasoned business leader with a strong focus on innovation, collaboration and policy, driven by a purpose to improve healthcare access and outcomes.
Our stellar Scientific Advisory Board includes cell and gene therapy inventors and leaders
Our global outlook, development strategy and collaborations are enabled by our luminous scientific advisory board which consists of some of the most prominent names in the world of cell and gene therapy. Their stellar track records in research and its translation to life-saving therapies give assurance and heft to our capabilities. We are advised by the best in the field, to bring the best to India.
Barbara and Edward Netter Professor in Cancer Gene Therapy
Deputy Director-Technology Innovation and Assessment, Center for Cellular Immunotherapies
Founding Director, Clinical Cell and Vaccine Production Facility
A co-inventor of the first FDA approved gene therapy, Prof. Levine has conducted first in-human adoptive immunotherapy trials using CAR-T cells, the first infusions of gene edited cells, the first human use of a lentiviral vector for gene delivery, and the first use of lentivirus modified cells to treat cancer.
The Clinical Cell and Vaccine Production Facility develops and tests novel cell and gene therapies in clinical trials in hematologic malignancies, solid tumors, HIV infection and genetic disease.
Prof. Levine holds 27 US patents. He has authored and co-authored >180 manuscripts and book chapters with a Google Scholar citation h-index of 85.
- William Osler Patient Oriented Research Award
- Wallace H. Coulter Award for Healthcare Innovation
- President of the International Society for Cell and Gene Therapy
- Appointed to the Board of Directors of the Alliance for Regenerative Medicine
Richard W. Vague Professor, the Department of Pathology and Laboratory Medicine, University of Pennsylvania
Director, Center for Cellular Immunotherapies, Perleman School of Medicine
Immunotherapy pioneer and career immunologist. Dr June is credited with the development of T-cell therapy for cancer (CAR-T).
He has published more than 350 manuscripts. He presently leads research in the mechanisms of lymphocyte activation relating to immune tolerance and adoptive immunotherapy for cancer and chronic infection.
- Named 2021 Dan David Prize Laureate
- Elected to the National Academy of Sciences, 2020
- Elected to the American Academy of Arts and Sciences, 2014
- Elected to the Institute of Medicine, 2012
Director, Center for Multiple Myeloma, Massachusetts General Hospital
Rita Kelly Chair in Oncology, Professor of Medicine, Harvard Medical School.
A translational researcher, Dr. Raje is an authority in the field of multiple myeloma having published extensively towards its research. A member of numerous cancer societies and a reviewer for several scientific journals. Dr Raje consults with leading pharma companies.
She presently leads research in understanding the biology and treatment of multiple myeloma with novel therapeutics.
- Claflin Distinguished Scholar award
- Leukemia and Lymphoma Society Clinical Scholar Award
Chief Technical Officer, Instil Bio
A seasoned technical leader with extensive experience in development and manufacturing of recombinant proteins, monoclonal antibodies, gene and cell therapy products. More than 2 decades of leadership responsibilities across various positions in process development, manufacturing and quality at organizations – Scios, Avigen, Hoffmann-La Roche, Johnson & Johnson, Amgen and Kite (a Gilead company).
Instrumental in handling CMC/process development responsibilities at Kite, which led to approval of two cell therapy products, Yescarta® and Tecartus®.
- Member of PDA ATMP Advisory Board
- Member of PDA Bio Advisory Board
- PDA Process Validation Interest Group Leader
Our approach: From bench to bedside
Committed to Make in India with Assured Quality, in everything we do.
Immuneel has built end to end capabilities and processes including cGMP lentiviral vector manufacturing to assure the delivery of high-quality, cost-effective cell therapy in India, maximizing value and efficiency, scientifically.
- Access to the right manufacturing platforms for cell therapy and lentiviral vectors.
- Focus on stringent cGMP, a clean room by itself is NOT GMP.
- Investing in advanced analytics & Quality control experts.
- Committed to cost effective operations & better cost control across the value chain.
- Strategically located: In – hospital manufacturing and access to clinical infrastructure (close to a bone marrow transplant unit).
- Focussed on making high quality, next generation cell therapies accessible to patients, affordably.
- Collaborate with the government & hospital chains to deliver to India.
- Committed to best science and clinical outcomes.
Our multi-product, multi-process facilities are designed to be globally compliant with semi-integrated, semi-automated closed cell manufacturing processes.
We are building a digital paper-less ecosystem that monitors our facilities, instruments and documents, processes, research, learning and compliance in keeping with our commitment to the environment. Our strategically located hub and decentralized model ensures delivery of quality products to our patients, regardless of their location. Our network of advisors and partners coupled with our team’s diverse experience are key enablers in our path to success in delivering our Smart Cell Therapies.
India’s first Integrated Cell Therapy Development & Manufacturing Facility inauguration (from left to right Dr. Renu Swarup, Dr. Arun Anand, Ms. Kiran M Shaw and Dr. Devi Shetty)
Welcoming the future
State-of-the-art CGT facility
Inauguration of Immuneel’s cGMP. (from left to right) Dr. Arun Anand, Ms. Kiran M Shaw, Dr. Devi Shetty, Dr. Kush Parmar
(from left to right) Dr. Carl H June, Dr. Siddhartha Mukherjee and Dr. Arun Anand attending Immuneel’s 1st Science Summit ‘celltalk’
Immuneel’s integrated multi-product facility
Immuneel team with Dr. Carl H June & Dr. Sharat Damodar at ASH Annual Meeting 2022, USA
Immuneel team with Dr. Noopur Raje
Immuneel with Hospital Clinic Barcelona team at EHA Annual Meeting 2023, Germany
Immuneel presents at Cellicon Valley’23, USA (with Dr. Bruce Levine)
(from left to right) Dr. Carl H June, Dr. Siddhartha Mukherjee and Dr. Bruce Levine at Immuneel’s milestone – Cellicon Valley’23, USA
Immuneel awarded ‘Biopharma’s most promising startups 2023’ – Endpoints 11
